CT Imaging for Guiding PA-TACE for HCC
Recruiting
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Procedure: postoperative adjuvant transarterial chemoembolization
- Registration Number
- NCT06156748
- Lead Sponsor
- Zhujiang Hospital
- Brief Summary
Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1488
Inclusion Criteria
- CT scans acquired no more than one month before surgery
- Confirmation of HCC diagnosis by pathological examination
- Curative surgical resection
Exclusion Criteria
- Prior antitumor treatment
- Macrovascular thrombosis or metastasis
- Perioperative mortality
- Unqualified image artifacts
- Tumor rupture
- MVI status not reported
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Hepatectomy alone postoperative adjuvant transarterial chemoembolization -
- Primary Outcome Measures
Name Time Method Overall survival the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months. Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
ZhuJiang Hospital of Southern Medical University
🇨🇳Guangzhou, Guangdong, China